Clinical progress on bortezomib in the treatment for multiple myeloma was reviewed.
该文综述了硼替佐米治疗多发性骨髓瘤的临床应用进展.
互联网
Conclusion: Bortezomib alone or in combination with irinotecan in patients with relapsed or refractory CRC.
结论: 单用硼替佐米或联合伊立替康对复发或耐药的结直肠癌无效.
互联网